Abstract
Aldosterone has an important role in end-organ damage in hypertension, post-MI-cardiac remodelling, and heart failure. Accordingly blockers of the aldosterone receptor such as spironolactone and eplerenone have gained widespread use in the treatment of (post-MI) heart failure. The article outlines the clinical evidence on the efficacy of aldosterone blocking agents in heart failure and hypertension and outlines clinical perspectives for their use.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
